NovaBay Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

NovaBay Pharmaceuticals wird ein Gewinn- und Umsatzwachstum von 124.5% bzw. 14.4% pro Jahr prognostiziert, während der Gewinn pro Aktie um 148.6% pro Jahr wachsen soll.

Wichtige Informationen

70.5%

Wachstumsrate der Gewinne

130.4%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.8%
Wachstumsrate der Einnahmen	7.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	30 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think NovaBay Pharmaceuticals (NYSEMKT:NBY) Can Afford To Drive Business Growth

Mar 29

Gewinn- und Umsatzwachstumsprognosen

NYSEAM:NBY - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	16	-3	N/A	0	1
12/31/2025	14	-4	N/A	-3	2
12/31/2024	11	-6	N/A	-4	2
6/30/2024	14	-17	-3	-3	N/A
3/31/2024	15	-19	-4	-4	N/A
12/31/2023	15	-17	-4	-4	N/A
9/30/2023	13	-15	-5	-5	N/A
6/30/2023	13	-19	-6	-6	N/A
3/31/2023	13	-17	-6	-6	N/A
12/31/2022	14	-16	-7	-7	N/A
9/30/2022	14	-9	-10	-10	N/A
6/30/2022	13	-5	-10	-10	N/A
3/31/2022	12	-5	-10	-10	N/A
12/31/2021	10	-7	-9	-9	N/A
9/30/2021	9	-7	-6	-6	N/A
6/30/2021	8	-8	-6	-6	N/A
3/31/2021	10	-11	-5	-5	N/A
12/31/2020	10	-11	-5	-5	N/A
9/30/2020	10	-13	-5	-5	N/A
6/30/2020	9	-10	-5	-5	N/A
3/31/2020	7	-8	-6	-6	N/A
12/31/2019	7	-10	-8	-8	N/A
9/30/2019	8	-8	-9	-8	N/A
6/30/2019	10	-10	-9	-9	N/A
3/31/2019	11	-9	-8	-8	N/A
12/31/2018	13	-7	-6	-6	N/A
9/30/2018	15	-4	-7	-7	N/A
6/30/2018	16	-5	-5	-5	N/A
3/31/2018	17	-6	N/A	-5	N/A
12/31/2017	18	-7	N/A	-6	N/A
9/30/2017	16	-10	N/A	-4	N/A
6/30/2017	15	-11	N/A	-8	N/A
3/31/2017	14	-12	N/A	-9	N/A
12/31/2016	12	-13	N/A	-12	N/A
9/30/2016	9	-16	N/A	-16	N/A
6/30/2016	7	-17	N/A	-16	N/A
3/31/2016	6	-19	N/A	-19	N/A
12/31/2015	4	-19	N/A	-19	N/A
9/30/2015	3	-19	N/A	-18	N/A
6/30/2015	2	-18	N/A	-17	N/A
3/31/2015	1	-16	N/A	-15	N/A
12/31/2014	1	-15	N/A	-15	N/A
9/30/2014	1	-15	N/A	-16	N/A
6/30/2014	2	-14	N/A	-15	N/A
3/31/2014	3	-16	N/A	-14	N/A
12/31/2013	3	-16	N/A	-13	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NBY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: NBY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: NBY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: NBYDie Einnahmen des Unternehmens (7.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: NBYDie Einnahmen des Unternehmens (14.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von NBY in 3 Jahren voraussichtlich hoch sein wird

NovaBay Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 15%, EPS upgraded

Novabay Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.27 loss, revenue downgraded

Consensus EPS estimates fall by 56%

Consensus revenue estimates increase by 20%

Recent updates

Consensus revenue estimates decrease by 15%, EPS upgraded

New major risk - Negative shareholders equity

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

NovaBay Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024

NovaBay Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Novabay Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

NYSE American Accepts NovaBay Pharmaceuticals Plan of Compliance

No longer forecast to breakeven

NovaBay Pharmaceuticals Provides Non-Compliance Update

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 28, 2024

Consensus EPS estimates upgraded to US$0.27 loss, revenue downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY).

New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $1.07 million.

New minor risk - Share price stability

NovaBay Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Novabay Pharmaceuticals, Inc. Announces Commercial Launch of Avenova Allograft

Consensus EPS estimates fall by 56%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profitability

NovaBay Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Novabay Pharmaceuticals, Inc. Announces Audrey Kunin to Retire and Resign from Her Position as Chief Product Officer Effective as of November 5, 2023

Novabay Pharmaceuticals, Inc. Approves to Elect Mijia (Bob) Wu as Director

NovaBay Pharmaceuticals, Inc. Announces DERMAdoctor's KP Duty Lotion and Scrub Ultra Duo Set for Dry, Rough, Bumpy Skin to Be Featured on QVC at a Special Price

NovaBay Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2023

Consensus revenue estimates increase by 20%

No longer forecast to breakeven

NovaBay Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

NovaBay Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 23, 2023

Novabay Pharmaceuticals, Inc. Announces Executive Changes

Consensus forecasts updated

Consensus EPS estimates fall by 57%

Price target decreased to US$39.88

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

NovaBay Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Novabay Pharmaceuticals, Inc. Announces Newest Addition to the Dermadoctor Picture Porefect Collection 15% Niacinamide Pore Minimizing Serum

NovaBay Pharmaceuticals, Inc.’ Avenova and DERMAdoctor Products to be Featured During the October 11-12 Amazon Prime Early Access Sale

NovaBay Pharmaceuticals Receives NYSE American Notice Regarding Low Share Price

Consensus EPS estimates fall by 13%

Price target decreased to US$2.80

NovaBay Pharmaceuticals, Inc. announced that it expects to receive $3.25 million in funding

Consensus EPS estimates fall by 14%

Price target decreased to US$2.98

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

NovaBay Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Novabay Pharmaceuticals, Inc. Announces Availability of Select Dermadoctor Products

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

NovaBay Pharmaceuticals, Inc. Expands DERMAdoctor Kakadu C and Calm Cool + Corrected Collections with New Anti-Aging Formulations

NovaBay Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

NovaBay Pharmaceuticals, Inc. Introduces Hydrating Cleansing Oil to Its Dermadoctor Calm Cool + Corrected Product Line

Full year 2021 earnings: EPS and revenues miss analyst expectations

NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022

Novabay Pharmaceuticals Announces Changes to Its Board of Directors

Novabay Pharmaceuticals Expands Its Eyecare Product Portfolio with the Launch of Lubricating Eye Drops for the Immediate Relief of Dry Eye Symptoms

Forecast to breakeven in 2024

Novabay Pharmaceuticals, Inc. Announces DERMAdoctor’s Calm Cool + Corrected Eczema Balm Receives National Eczema Association Seal of Acceptance

Chief Product Officer recently bought US$125k worth of stock

Price target increased to US$3.10

Consensus forecasts updated

Third quarter 2021 earnings released: US$0.051 loss per share (vs US$0.08 loss in 3Q 2020)

Price target increased to US$2.85

Consensus EPS estimates fall to -US$0.16

Second quarter 2021 earnings released: US$0.044 loss per share (vs US$0.15 loss in 2Q 2020)

Senior Manager & Controller Wang Xu has left the company